ASP546C Clinical Trials (2026): 1 Studies for Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma & Pancreatic Adenocarcinoma

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

1 ASP546C clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma & Pancreatic Adenocarcinoma) and 150 total planned enrollment. 1 ASP546C clinical trial is actively recruiting at 9 U.S. sites across 6 states. Most recent activity: NCT07488676 (Jul 2029).

Where to Participate: All ASP546C Trial Sites in the U.S. (9 sites across 6 states)

Every actively recruiting ASP546Ctrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
CASTART Los AngelesLos Angeles90025NCT07488676Map
MISTART MidwestGrand Rapids49546NCT07488676Map
NYSTART New YorkLake Success10042NCT07488676Map
NCDuke Cancer Center DurhamDurham27710NCT07488676Map
TXNext Oncology - AustinAustin78758NCT07488676Map
TXNext Oncology - HoustonHouston77054NCT07488676Map
TXNext Oncology - DallasIrving75039NCT07488676Map
TXSTART San AntonioSan Antonio78229NCT07488676Map
UTSTART Mountain RegionWest Valley City84119NCT07488676Map

ASP546C clinical trials at a glance: phase × recruitment status

PhaserecruitingTotal
P1/P211

Recruiting ASP546C clinical trials (1)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT07488676A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsP1/P2Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma150May 2026

All ASP546C trials (1)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT07488676A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsP1/P2recruiting150Astellas Pharma Global Development, Inc.May 2026

ASP546C clinical trials: frequently asked questions

How many ASP546C clinical trials are there?
1 ASP546C clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
Are ASP546C clinical trials recruiting in 2026?
Yes — 1 ASP546C trial is actively recruiting in 2026, with 9 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
What conditions is ASP546C being studied for?
ASP546C is being studied for Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma. The trials are grouped by indication on this page.
Who sponsors ASP546C clinical trials?
The lead sponsor across the most ASP546C trials is Astellas Pharma Global Development, Inc.. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming ASP546Cas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: